Korean J Gastroenterol.  2020 Feb;75(2):112-114. 10.4166/kjg.2020.75.2.112.

Recent Advances in the Pathogenesis and Treatment of Functional Dyspepsia with Focus on the Duodenum

• Cha RR
• Kim HJ

• KMID: 2471152
• DOI: http://doi.org/10.4166/kjg.2020.75.2.112

Abstract

No abstract available.

MeSH Terms

Duodenum*
Dyspepsia*

Reference

References

1. Vanheel H, Carbone F, Valvekens L, et al. Pathophysiological abnormalities in functional dyspepsia subgroups according to the Rome III criteria. Am J Gastroenterol. 2017; 112:132–140.

2. Walker MM, Talley NJ. The role of duodenal inflammation in functional dyspepsia. J Clin Gastroenterol. 2017; 51:12–18.

3. van Baar ACG, Nieuwdorp M, Holleman F, Soeters MR, Groen AK, Bergman JJGHM. The duodenum harbors a broad untapped therapeutic potential. Gastroenterology. 2018; 154:773–777.

4. Camilleri M. Gastrointestinal hormones and regulation of gastric emptying. Curr Opin Endocrinol Diabetes Obes. 2019; 26:3–10.

5. Jung HK, Talley NJ. Role of the duodenum in the pathogenesis of functional dyspepsia: a paradigm shift. J Neurogastroenterol Motil. 2018; 24:345–354.

6. Lee KJ, Kim JH, Cho SW. Dyspeptic symptoms associated with hypersensitivity to gastric distension induced by duodenal acidification. J Gastroenterol Hepatol. 2006; 21:515–520.

7. Lee KJ, Demarchi B, Demedts I, Sifrim D, Raeymaekers P, Tack J. A pilot study on duodenal acid exposure and its relationship to symptoms in functional dyspepsia with prominent nausea. Am J Gastroenterol. 2004; 99:1765–1773.

8. Bratten J, Jones MP. Prolonged recording of duodenal acid exposure in patients with functional dyspepsia and controls using a radiotelemetry pH monitoring system. J Clin Gastroenterol. 2009; 43:527–533.

9. Vanheel H, Farré R. Changes in gastrointestinal tract function and structure in functional dyspepsia. Nat Rev Gastroenterol Hepatol. 2013; 10:142–149.

10. Fried M, Feinle C. The role of fat and cholecystokinin in functional dyspepsia. Gut. 2002; 51(Suppl 1):i54–i57.

11. Simrén M, Vos R, Janssens J, Tack J. Acid infusion enhances duodenal mechanosensitivity in healthy subjects. Am J Physiol Gastrointest Liver Physiol. 2003; 285:G309–G315.

12. Vanuytsel T, Karamanolis G, Van Oudenhove L, Vos R, Tack J. Influence of ondansetron on gastric sensorimotor responses to short duodenal acid infusion in healthy volunteers. Neurogastroenterol Motil. 2011; 23:226–232. e115.

13. Talley NJ, Ford AC. Functional dyspepsia. N Engl J Med. 2016; 374:896.

14. Moayyedi P, Lacy BE, Andrews CN, Enns RA, Howden CW, Vakil N. ACG and CAG clinical guideline: management of dyspepsia. Am J Gastroenterol. 2017; 112:988–1013.

15. Jackson MA, Goodrich JK, Maxan ME, et al. Proton pump inhibitors alter the composition of the gut microbiota. Gut. 2016; 65:749–756.

16. Imhann F, Bonder MJ, Vich Vila A, et al. Proton pump inhibitors affect the gut microbiome. Gut. 2016; 65:740–748.

17. Friesen CA, Neilan NA, Schurman JV, Taylor DL, Kearns GL, Abdel-Rahman SM. Montelukast in the treatment of duodenal eosinophilia in children with dyspepsia: effect on eosinophil density and activation in relation to pharmacokinetics. BMC Gastroenterol. 2009; 9:32.

18. Jung HK, Keum BR, Jo YJ, et al. Diagnosis of functional dyspepsia: a systematic review. Korean J Gastroenterol. 2010; 55:296–307.

19. Darkoh C, Lichtenberger LM, Ajami N, Dial EJ, Jiang ZD, DuPont HL. Bile acids improve the antimicrobial effect of rifaximin. Antimicrob Agents Chemother. 2010; 54:3618–3624.